Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe Psoriasis

NCT04271540 is registered in ClinicalTrials.gov with Marcelo F. Di Carli, MD, FACC as lead sponsor.

NCT NCT04271540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04271540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe Psoriasis
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Phase
Phase 4
Overall status
Completed
Start date
April 4, 2020
Completion date
July 17, 2024
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, psoriasis